FindTrial
Sign In

Effects of Immersive and Non- Immersive Virtual Reality Games on Anxiety and Cognition in Parkinson's Disease

Usability, applicability, and therapeutic potential of Different Virtual Reality Systems in patients with Neurological, Rheumatological, and Orthopedic Injuries -

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8z285wq
Enrollment
Unknown
Registered
2024-01-17
Start date
2017-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease

Interventions

The present study was a non-randomized, blind, controlled, clinical trial that was approved by the Ethics and Research Committee of the Faculty of Ceilandia-FCE- at the University of Brasília (UnB) an
L01.224.160.875

Sponsors

Faculdade de Ceilândia - Universidade de Brasília-UnB
Lead Sponsor
Faculdade de Ceilândia - Universidade de Brasília-UnB
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: The inclusion criteria were completed elementary education; a minimum score of 24 on the mini mental state examination; a score below 7 on the Geriatric Depression Scale; a score between 1 and 3 on the Hoehn and Yahr Scale (mild/moderate); absence of auditory or visual deficits that would impair participation in the virtual reality training

Exclusion criteria

Exclusion criteria: The exclusion criteria were any clinical condition that would compromise the intervention; previous experience with gaming consoles and/or attending another specialized rehabilitation program during the training; history of motion sickness; dizziness; seizures; epilepsy; active nausea

Design outcomes

Primary

MeasureTime frame
Expected Outcome 1: Reduction of anxiety levels assessed by the Beck Anxiety Inventory using virtual reality.;Outcome found 1:The findings revealed a significant decrease in the BAI score in the IVR group (F=15,217; p<0.001) between T1 13.5 (8,5 – 15,8) and T7 10,0 (6,1 - 11,4) and between T1 13,5 (8,5 – 15,8) and T30 6,5 (4,5 – 8,9). After the intervention with IVR, there was a reduction of approximately 27% in anxiety between T1 and T7, leading to a change in classification on the BAI anxiety scale from moderate to mild anxiety level. Furthermore, there was a reduction of 44% in anxiety levels between T1 and T30, also resulting in a change from mild anxiety to minimal anxiety in BAI scale classification.—

Secondary

MeasureTime frame
No secondary outcome are expected.—

Countries

Brazil

Contacts

Public ContactAline Araujo do Carmo

Faculdade de Ceilândia - Universidade de Brasília-UnB

alinecarmo@unb.br+5579988797681

Outcome results

None listed

Source: REBEC (via WHO ICTRP)